Last 15 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -7.99 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 7.43 | 4.64 | 2.82 | 2.47 | 3.22 | 2.55 | 1.99 | 1.77 | 1.43 | 1.44 | — | 1.31 | — |
| — | +82.4% | +41.9% | +39.9% | +124.9% | +77.0% | — | +34.8% | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -82.2% | -8.3% | -13.2% | -15.8% | -22.9% | -21.4% | -13.3% | -11.1% | -9.7% | -8.3% | -4.2% | -10.4% | — |
| — | +61.2% | +0.4% | -43.1% | -136.8% | -157.9% | -217.5% | -7.0% | — | — | +96.6% | — | — | |
| ROA | -77.7% | -7.9% | -12.5% | -15.1% | -20.6% | -19.2% | -12.3% | -10.5% | -9.2% | -8.0% | -4.1% | -6.0% | -7.7% |
| — | +58.9% | -1.7% | -43.1% | -124.0% | -140.0% | -203.3% | -75.6% | -20.3% | -46.7% | — | +90.6% | — | |
| ROIC | -107.3% | -10.8% | -18.1% | -26.3% | -35.8% | -24.9% | -14.7% | -12.4% | -11.2% | -10.9% | -6.9% | -126.9% | — |
| — | +56.6% | -22.6% | -112.8% | -218.4% | -128.6% | -113.2% | +90.3% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 198.3% YoY to 25.50x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 14.02 | 25.50 | 15.12 | 26.48 | 14.02 | 8.55 | 11.20 | 18.06 | 23.76 | 19.59 | 43.42 | 26.07 | 13.98 |
| — | +198.3% | +35.0% | +46.6% | -41.0% | -56.4% | -74.2% | -30.7% | +69.9% | +16.1% | — | +1084.6% | — | |
| Quick Ratio | 14.02 | 25.50 | 15.12 | 26.48 | 14.02 | 8.55 | 11.20 | 18.06 | 23.76 | 19.59 | 43.42 | 26.07 | 13.98 |
| — | +198.3% | +35.0% | +46.6% | -41.0% | -56.4% | -74.2% | -30.7% | +69.9% | +16.1% | — | +1084.6% | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 15 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonMineralys Therapeutics, Inc.'s current P/E is -8.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Mineralys Therapeutics, Inc.'s business trajectory between earnings reports.